SAN FRANCISCO -- February 22, 2010 -- Researchers said here during the 17th Conference on Retroviruses and Opportunistic Infections (CROI) that they could not find a link between most cancers and a diagnosis of AIDS.
During a poster presentation Meredith Shiels, PhD, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, said the researchers did not find a connection between...
Second malignant neoplasm risk high for Hodgkin’s lymphoma, despite initial low-dose radiation
HemOnc today
Posted February 11, 2010
Children with Hodgkin’s lymphoma remained at high risk for second malignant neoplasms, even when treated with low-dose radiation, according to the results of a long-term follow-up study. Researchers said patients treated with low-dose radiation developed sarcomas and breast and thyroid carcinomas with similar frequency and latency as...
Patients with certain HL at risk for transformation to aggressive lymphoma years later
HemOnc today
Posted February 4, 2010
The risk for transformation to aggressive lymphoma, commonly diffuse large B-cell lymphoma, was substantial in patients with nodular lymphocyte-predominant Hodgkin’s lymphoma and may occur decades after the original diagnosis.
According to background information in the study, patients with nodular lymphocyte-predominant Hodgkin’s...
Seattle Genetics and Millennium Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma
Businesss Wire
February 03, 2010 09:00 AM Eastern Time
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy...
